113.63
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$111.44
Aprire:
$112.32
Volume 24 ore:
336.62K
Relative Volume:
0.32
Capitalizzazione di mercato:
$27.32B
Reddito:
$2.97B
Utile/perdita netta:
$-812.83M
Rapporto P/E:
-33.46
EPS:
-3.3962
Flusso di cassa netto:
$-1.24B
1 W Prestazione:
+0.95%
1M Prestazione:
+10.24%
6M Prestazione:
-7.01%
1 anno Prestazione:
+32.81%
Biontech Se Adr Stock (BNTX) Company Profile
Confronta BNTX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BNTX
Biontech Se Adr
|
113.63 | 26.60B | 2.97B | -812.83M | -1.24B | -3.3962 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
478.74 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
575.25 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
327.47 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
570.09 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.20 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-05 | Reiterato | H.C. Wainwright | Buy |
2025-05-29 | Iniziato | Goldman | Neutral |
2025-03-13 | Iniziato | Citigroup | Buy |
2025-01-10 | Iniziato | Truist | Buy |
2024-12-11 | Iniziato | Wells Fargo | Overweight |
2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
2024-11-19 | Iniziato | Berenberg | Buy |
2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
2024-05-14 | Iniziato | Evercore ISI | In-line |
2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
2024-01-05 | Iniziato | Oppenheimer | Perform |
2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
2023-07-14 | Iniziato | HSBC Securities | Buy |
2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
2022-08-17 | Iniziato | Cowen | Market Perform |
2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2022-07-06 | Ripresa | Canaccord Genuity | Buy |
2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2021-10-22 | Iniziato | Deutsche Bank | Hold |
2021-10-07 | Iniziato | Jefferies | Hold |
2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
2021-07-19 | Ripresa | Wolfe Research | Outperform |
2021-06-16 | Downgrade | Redburn | Neutral → Sell |
2021-05-18 | Iniziato | Goldman | Neutral |
2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
2020-08-03 | Ripresa | Berenberg | Buy |
2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2020-01-22 | Downgrade | UBS | Buy → Neutral |
2019-11-05 | Iniziato | Wolfe Research | Outperform |
2019-11-04 | Iniziato | Berenberg | Buy |
2019-11-04 | Iniziato | BofA/Merrill | Buy |
2019-11-04 | Iniziato | Canaccord Genuity | Buy |
2019-11-04 | Iniziato | JP Morgan | Overweight |
2019-11-04 | Iniziato | SVB Leerink | Outperform |
2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
BioNTech’s New Study on PDAC Treatment: Key Insights for Investors - TipRanks
BioNTech’s BNT327 Clinical Trial: A New Hope for Small-Cell Lung Cancer? - MSN
Pfizer and BioNTech’s New Shingles Vaccine Study: What Investors Need to Know - TipRanks
BioNTech’s BNT327 Trial: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
BioNTech’s Promising Lung Cancer Trial: A Potential Game-Changer for NSCLC Treatment - TipRanks
BioNTech Announces Ryan Richardson to Step Down from the Management Board17.07.25News - Ariva
BioNTech’s DYNASTY-Breast02 Study: A New Hope for Metastatic Breast Cancer? - TipRanks
OneDigital Investment Advisors LLC Makes New Investment in BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Promising Phase III Trial for Recurrent Endometrial Cancer - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for Lung Cancer Treatment? - TipRanks
BioNTech’s Phase II Trial: A Potential Game-Changer in Colorectal Cancer Treatment - TipRanks
Regeneron and BioNTech’s Promising Lung Cancer Trial: What Investors Need to Know - TipRanks
BioNTech SE Receives Buy Rating from BMO Capital with $143 Price Target - AInvest
Genmab and BioNTech’s GEN1056 Study: A New Hope for Advanced Solid Tumors - TipRanks
Genmab and BioNTech’s Immunoradiotherapy Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope for Cancer Treatment? - TipRanks
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
GAMMA Investing LLC Sells 334 Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) - Defense World
BioNTech’s Phase III Trial: A Potential Game-Changer in Endometrial Cancer Treatment - TipRanks
Genmab and BioNTech’s Promising Immunoradiotherapy Study for Metastatic Tumors - TipRanks
Genmab and BioNTech’s Pioneering Cancer Trial: A Potential Game-Changer? - TipRanks
Genmab and BioNTech’s GEN1056 Study: A Potential Game-Changer in Oncology - TipRanks
Genmab and BioNTech’s GEN1042 Study: A New Hope in Cancer Treatment - TipRanks
Genmab and BioNTech’s GEN1042 Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s BNT151 Study Update: Early Termination and Market Implications - TipRanks
BioNTech ADR Earns Relative Strength Rating Upgrade - MSN
Biontech SE’s BNT317 Study: A New Hope for Advanced Solid Tumors - TipRanks
BioNTech’s Latest Clinical Trial: A New Hope for NSCLC Treatment? - TipRanks
What is HC Wainwright’s Forecast for BioNTech Q3 Earnings? - Defense World
BioNTech ADR Gets Relative Strength Rating Upgrade - Investor's Business Daily
BioNTech’s Promising Phase II Study: A Potential Game-Changer in Cancer Treatment - TipRanks
BioNTech SE’s Promising Study on Pancreatic Cancer Treatment: What Investors Need to Know - TipRanks
BioNTech’s BNT327: A Promising Phase II Trial for Small-Cell Lung Cancer - TipRanks
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Zacks Investment Research
Equities Analysts Issue Forecasts for BioNTech Q4 Earnings - Defense World
BioNTech (BNTX) – Analysts’ Recent Ratings Changes - Defense World
Private-Public Deal Momentum Grows, Yet Megamergers Stay Elusive - Investing.com
HC Wainwright Estimates BioNTech’s Q4 Earnings (NASDAQ:BNTX) - Defense World
Market Update: Abercrombie & Fitch Co (ANF) Sees Positive Movement, Closing at 75.00 - DWinneX
Gaining Ground: fuboTV Inc (FUBO) Closes Higher at 3.26, Up 2.84 - DWinneX
Market Resilience: Nerdy Inc (NRDY) Finishes Strong at 1.63, Up 2.52 - DWinneX
5 Stocks To Ride The German Market RallyCureVac (NASDAQ:CVAC), BioNTech (NASDAQ:BNTX) - Benzinga
Riding the Waves: A Guide to Investing in ARBE Stock - investchronicle.com
BMY Reports Positive Data On Sotyktu From Arthritis Study - Barchart.com
Erasca Inc (ERAS) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
CureVac stock soars about 30% after BioNTech agrees to acquire co By Investing.com - Investing.com South Africa
Vaccine stocks muted as investors assess Kennedy’s overhaul of key panel - The Globe and Mail
Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading - Benzinga
BMY Collaborates for Oncology Drug: Will This Boost Its Portfolio? - The Globe and Mail
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):